Thalassaemia in Pregnancy
On this page
Direct answer
Beta-thalassaemia major meets pregnancy as a transfusion-dependent, iron-overloaded, often infertile-by-default condition that demands cardiology-grade preconception assessment; beta-thalassaemia trait meets it as a mild microcytic anaemia that must not be treated with iron blindly. Trait diagnosis rests on haemoglobin A2 above 3.5 per cent on HPLC with low mean corpuscular volume, and the critical antenatal task is partner testing — if both partners carry the trait, chorionic villus sampling at 10-12 weeks offers prenatal diagnosis, since India records an estimated 10,000-plus thalassaemia major births annually. Alpha-thalassaemia matters differently: the severe deletion genotype produces Hb Bart's hydrops fetalis, a fatally oedematous fetus with placental thickening and maternal pre-eclampsia risk. Transfusions in major disease target a haemoglobin around 10 g/dL; chelation continues with agents of safer pedigree, and fetal surveillance is intensified.
What you must remember
- Trait versus major: trait (minor) is a mild hypochromic microcytic anaemia (Hb rarely below 10 g/dL, MCV under 76-80 fL) needing only folic acid; major is transfusion-dependent with iron overload, splenomegaly and end-organ damage — two entirely different pregnancies.
- Diagnostic numbers: HbA2 more than 3.5-4 per cent confirms beta-thalassaemia trait on HPLC; iron studies distinguish it from iron deficiency (high, not low, ferritin); pregnancy can falsely lower HbA2 toward the third trimester.
- Prenatal diagnosis ladder: both-partner HPLC screening, genetic counselling, then first-trimester chorionic villus sampling (10-12 weeks) or amniocentesis (15-16 weeks) when both are carriers; preimplantation genetic testing is the IVF-route option.
- Alpha-thalassaemia corner: deletion of all four alpha genes (– –/– –) gives Hb Bart's hydrops fetalis — grossly oedematous fetus, large placenta, maternal pre-eclampsia and delivery complications; three-gene deletion gives HbH disease, a moderately severe haemolytic anaemia.
- Transfusion targets in major: keep haemoglobin around 9.5-10.5 g/dL through pregnancy; transfuse with leucodepleted packed cells and monitor for alloimmunisation.
- Iron and chelation: deferasirox and deferiprone are generally avoided in pregnancy (teratogenicity/limited data) while desferrioxamine (deferoxamine) at moderate doses is the traditional choice when chelation cannot be paused — a nuanced, frequently examined distinction.
- Preconception musts in major disease: cardiac T2 MRI for myocardial iron (left ventricular dysfunction is the killer), endocrine review for diabetes and hypothyroidism, hepatitis status, and a frank fertility discussion since ovulation induction is commonly needed.
- Fetal surveillance: growth scans for the transfused mother, and paternal testing in every case so the fetal risk arithmetic is explicit.
A typical exam case
A 27-year-old with beta-thalassaemia major, married and pregnant after ovulation induction, attends at 8 weeks. Walk the reasoning: first the heart — a cardiac MRI T2 above about 20 ms with normal ventricular function clears her; an ejection fraction below 55-60 per cent is the red flag that turns counselling toward termination discussions in extreme cases. Second the transfusion rhythm — schedule packed cells to hold Hb near 10 g/dL, accept the physiological dilution of the second trimester, and watch ferritin climb without panicking. Third the chelation question — pause oral chelators, use deferoxamine if iron load is dangerous, and defend that choice at the viva. Fourth the fetus — anomaly scan at 18-20 weeks, growth trajectory from 26 weeks, delivery at a unit with neonatal support.
Contrast the other consult the same week: a healthy woman with MCV 68 fL and Hb 10.8 g/dL. Her pathway is HPLC, partner HPLC, and reassurance — iron only if ferritin is low, because iron-loading a non-deficient trait does nothing but harm.
Where students slip
Two errors dominate. The first is treating every microcytic anaemia in pregnancy with iron: in thalassaemia trait, iron is useless (there is no deficiency) and a raised ferritin should stop the prescription — the Mentzer index (MCV/RBC, under 13 in trait) is the cheap bedside discriminator, though HPLC settles it. The second is mishandling Hb Bart's hydrops: candidates remember the oedematous fetus but forget the mother — she faces pre-eclampsia, antepartum haemorrhage from the huge placenta, and difficult delivery, so induction rather than expectant waiting is usually chosen.
Frequently asked questions
Which investigation confirms beta-thalassaemia trait in pregnancy?
Haemoglobin A2 estimation by HPLC — a level above 3.5-4 per cent with microcytosis confirms the trait, though late pregnancy can dilute the value slightly downward.
What is the risk when both partners have beta-thalassaemia trait?
Each pregnancy carries a 25 per cent chance of thalassaemia major, so prenatal diagnosis by chorionic villus sampling at 10-12 weeks is offered after counselling.
Which chelation agent is preferred if chelation cannot be stopped in pregnancy?
Deferoxamine (desferrioxamine) has the longest pregnancy safety record at moderate doses; oral deferasirox and deferiprone are generally avoided.
What causes Hb Bart's hydrops fetalis?
Deletion of all four alpha-globin genes produces excess gamma-chain tetramers (Hb Bart's), severe fetal anaemia, hydrops and a bulky placenta; the fetus is not viable, and the mother risks pre-eclampsia.
Do women with thalassaemia major need fertility treatment?
Often yes — hypogonadotrophic hypogonadism from iron overload frequently causes infertility, so ovulation induction under joint endocrine-obstetric care is common, after cardiac fitness is documented.